HER2/neu: an increasingly important therapeutic target. Part 3: clinical applications and investigations

Author(s): Edward L Nelson

HER2/neu is the molecule that has been most successfully targeted for therapeutic intent in the field of oncology. This extraordinary clinical impact has been driven by basic and translational investigations along with astute development of a range of therapeutic agents. This is the third part of a comprehensive three-part review. The clinical applications of HER2/neu-targeted therapies will be reviewed for individual tumor types, including early and late phase clinical studies, building on the prior reviews of the biology of the EGF receptor family and the biological distribution of HER2/neu overexpression. This comprehensive survey will identify opportunities for therapeutic development and promising areas for future clinical investigations of HER2/neu-targeted therapies, highlighting HER2/neu as an increasingly important therapeutic target.